PHARMACOLOGICAL APPROACHES TARGETING INCRETIN HORMONES IN DIABETES MANAGEMENT

JPUMHS;2023:13:04,144-149. http://doi.org/10.46536/jpumhs/2023/13.04.485

Abstract

ABSTRACT OBJECTIVE: Changes in glycemic control, as measured by HbA1c levels, was the main end measures. Changes in body weight was secondary end measures. METHODOLOGY: Baseline evaluations were performed, which included demographic data, glycated hemoglobin levels (HbA1c) and body weight were measured. Comparisons were made with the values obtained after 12 weeks of intervention RESULTS: The value of HbA1C and body weight was determined at baseline and after 12 weeks of intervention and the findings had revealed that at baseline the value of HbA1C of group A was 7.8%±2.2 and body weight was 80.2kg±2.5 that had significantly p<0.001 reduced to 5.2%±2.5 and 74.3kg ± 2.9. The values of HbA1C in group B at baseline was 7.5%±3.2 that had significant p<0.001 reduced to 5.7%±2.4 and average weight that was 79.09kg±3.2 was reduced to 75.4kg±1.85 (p<0.001). In group C also the effects of standardized treatment had provided significant findings and the differences in the mean glycated hemoglobin levels and body weight was found to be significant p<0.001 CONCLUSION : Overall, incretin-based therapeutics provide patients with type 2 diabetes creative and efficient treatment choices, offering promise for improved disease control and quality of life. The advantages and safety profiles of these medicines in a larger patient population will be completely clarified by more study and long-term investigations.